ClinicalTrials.gg
CompletedNCT00742469Updated Dec 18, 2019Results posted

Rifaximin for Prevention of Travellers' Diarrhea

A Phase 3 interventional study of Rifaximin and Placebo in Diarrhea, sponsored by Bausch Health Americas, Inc.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-18.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.

Enrollment
10th of 19
210 · median 210
Started
2005
with 2 others
Phase 3
10 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
7 of 19
Bausch Health Americas, Inc.

Among the 19 studies testing rifaximin in Diarrhea, this one is the 10th largest by enrollment, is one of 3 that started in 2005, is one of 10 in phase 3, and was the 8th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing rifaximin in Diarrhea, or all of them as a file.
02

Study summary

The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.

Read the detailed description

To determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.

03

Conditions studied

  • Diarrhea

Keywords

  • TD
  • traveller's diarrhea
  • campylobacter
  • shigella
  • salmonella
  • E. coli
  • diarrhea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. travelling to Mexico within 72 hours of enrollment
  2. read and understand English
  3. in good health

Exclusion criteria

Exclusion Criteria:

  1. acute diarrhea within previous 7 days
  2. taken FQs (any drug in this class), macrolide, azalide, or trimethoprim-sulfamethoxazole within 7 days or enrollment or anytime during study.
  3. taken antidiarrheal medication within 24 hours of enrollment or anytime during study.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
210 participants (actual)

Study arms

  • Active comparator
    1

    Rifaximin

    Drug: Rifaximin

  • Placebo comparator
    2

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment

    The efficacy of 14 days of rifaximin 600 mg once daily (QD) compared with placebo when taken by healthy subjects to prevent travelers' diarrhea (TD) resulting from all causes.

    Time frame: 14 days

07

Results

Posted Dec 18, 2019

Participant flow

Participant flow — Overall Study
MilestoneTreatment Arm 1Placebo Arm
Started106104
Completed8869
Not completed1835

Outcome measures

PrimaryCumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment

The efficacy of 14 days of rifaximin 600 mg once daily (QD) compared with placebo when taken by healthy subjects to prevent travelers' diarrhea (TD) resulting from all causes.

Time frame:
14 days
Reported as:
Count of participants · Participants
Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment
ParticipantsTreatment ArmPlacebo Arm
Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment1548

Adverse events

Collected over 14 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm—0/106 (0%)81/106 (76.4%)
Placebo—0/104 (0%)93/104 (89.4%)
Most frequent other events
Most frequent other events
EventTreatment ArmPlacebo
DiarrheaGastrointestinal disorders62/10683/104
Abdominal PainGastrointestinal disorders46/10663/104
Defecation UrgencyGastrointestinal disorders33/10643/104
FlatulenceGastrointestinal disorders27/10629/104
Rectal tenesmusGastrointestinal disorders7/10613/104
headacheNervous system disorders9/10610/104
VomitingGastrointestinal disorders9/1068/104
HematocheziaGastrointestinal disorders5/1066/104
PyrexiaGeneral disorders6/1066/104

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Arm 1Placebo ArmTotal
Mean23.5 ± 9.1522.9 ± 7.2823.2 ± 8.26
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm 1Placebo ArmTotal
Female6670136
Male403474
08

Study locations

1 site
  • University of San Diego
    Guadalajara, Jalisco 45090, Mexico
09

References and documents

Publications

  • Martinez-Sandoval F, Ericsson CD, Jiang ZD, Okhuysen PC, Romero JH, Hernandez N, Forbes WP, Shaw A, Bortey E, DuPont HL. Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med. 2010 Mar-Apr;17(2):111-7. doi: 10.1111/j.1708-8305.2009.00385.x. PubMed 20412178 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Sep 2005 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2019, 14 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2008
First posted
Aug 27, 2008
Start
Jun 2005
Primary completionActual
Sep 2005
CompletionActual
Apr 2007
Results first posted
Dec 18, 2019
Last update
Dec 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00742469
Responsible party
Sponsor
First posted
Aug 27, 2008
Start date
Jun 2005
Primary completion
Sep 2005
Completion
Apr 2007
Results posted
Dec 18, 2019
Last update
Dec 18, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion